In this issue:
Etanercept effect in children with plaque psoriasis
Long-term drug survival on biological therapy
Biologic treatments for elderly patients
Monthly vitamin D supplementation in mild psoriasis
Risk of malignancy with systemic psoriasis treatment
Serious infections after systemically treated psoriasis
Psoriasis and metabolic syndrome
Switching of biologics in psoriasis
Serum human beta-defensin-2 for monitoring JAK inhibitor response
Ixekizumab for plaque psoriasis: long-term results
Secukinumab in moderate-to-severe psoriasis
Secukinumab cost-consequence study
Please login below to download this issue (PDF)